Effect of , and Supernatants on Serotonin Transporter Expression in Cells and Tissues

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2022 Mar 23

PMID 35316963

Authors

Yi-Ming Chen

Ying Li

Xin Wang

Ze-Lan Wang

Jun-Jie Hou

Shuai Su

Wei-Long Zhong

Xin Xu

Jie Zhang

Bang-Mao Wang

Yu-Ming Wang

Affiliations

Soon will be listed here.

Abstract

Background: (), (), and () are probiotics that are widely used in the clinical treatment of irritable bowel syndrome (IBS). Whether the supernatants of these three probiotics can improve gastrointestinal sensation and movement by regulating the serotonin transporter (SERT) expression needs to be clarified.

Aim: To investigate whether , and supernatants can upregulate SERT expression and .

Methods: Caco-2 and HT-29 cells were stimulated with probiotic culture supernatants for 12 and 24 h, respectively. A male Sprague-Dawley rat model of post-infectious irritable bowel syndrome (PI-IBS) was established and the rats were treated with phosphate-buffered saline (group A) and three probiotics culture supernatants (groups B, C, and D) for 4 wk. The levels of SERT were detected by quantitative PCR and western blotting.

Results: The levels of SERT at post-treatment 12 and 24 h were significantly elevated in Caco-2 cells treated with supernatant compared with those in the control group ( 0.05). Those levels were markedly upregulated in Caco-2 cells stimulated with and supernatants at 24 h ( 0.05). In addition, SERT expression in groups B, C, and D was significantly higher than that in group A in the 2nd wk ( 0.05). Increased SERT expression was only found in group D in the 3rd wk ( 0.05). However, there was no significant difference in SERT expression between the groups in the last week ( 0.05).

Conclusion: The supernatants of B. , and can upregulate SERT expression in intestinal epithelial cells and the intestinal tissues in the rat model of PI-IBS.

Citing Articles

Exploring Gut Microbiota Imbalance in Irritable Bowel Syndrome: Potential Therapeutic Effects of Probiotics and Their Metabolites.

Garcia Mansilla M, Rodriguez Sojo M, Lista A, Ayala Mosqueda C, Ruiz Malagon A, Galvez J Nutrients. 2025; 17(1.

PMID: 39796588 PMC: 11723002. DOI: 10.3390/nu17010155.

Interplay of Transcriptomic Regulation, Microbiota, and Signaling Pathways in Lung and Gut Inflammation-Induced Tumorigenesis.

Otalora-Otalora B, Payan-Gomez C, Lopez-Rivera J, Pedroza-Aconcha N, Arboleda-Mojica S, Aristizabal-Guzman C Cells. 2025; 14(1.

PMID: 39791702 PMC: 11720097. DOI: 10.3390/cells14010001.

The Role of Gut Microbiome in Irritable Bowel Syndrome: Implications for Clinical Therapeutics.

Zhao Y, Zhu S, Dong Y, Xie T, Chai Z, Gao X Biomolecules. 2025; 14(12.

PMID: 39766350 PMC: 11674646. DOI: 10.3390/biom14121643.

Effects of Probiotic Supplementation on Body Weight, Growth Performance, Immune Function, Intestinal Microbiota and Metabolites in Fallow Deer.

Wang M, Guo Q, Shan Y, Cheng Z, Zhang Q, Bai J Biology (Basel). 2024; 13(8).

PMID: 39194541 PMC: 11351348. DOI: 10.3390/biology13080603.

Neuroprotective Effect of a Multistrain Probiotic Mixture in SOD1 Mice by Reducing SOD1 Aggregation and Targeting the Microbiota-Gut-Brain Axis.

Xin Z, Xin C, Huo J, Liu Q, Dong H, Li R Mol Neurobiol. 2024; 61(12):10051-10071.

PMID: 38349516 PMC: 11584480. DOI: 10.1007/s12035-024-03988-x.

References

Wang Y, Ge X, Wang W, Wang T, Cao H, Wang B . Lactobacillus rhamnosus GG supernatant upregulates serotonin transporter expression in intestinal epithelial cells and mice intestinal tissues. Neurogastroenterol Motil. 2015; 27(9):1239-48. DOI: 10.1111/nmo.12615. View

Cui X, Zhou W, Yang Y, Zhou J, Li X, Lin L . Epidermal growth factor upregulates serotonin transporter and its association with visceral hypersensitivity in irritable bowel syndrome. World J Gastroenterol. 2014; 20(37):13521-9. PMC: 4188903. DOI: 10.3748/wjg.v20.i37.13521. View

Hasler W . The irritable bowel syndrome. Med Clin North Am. 2003; 86(6):1525-51. DOI: 10.1016/s0025-7125(02)00086-x. View

Moayyedi P, Ford A, Talley N, Cremonini F, Foxx-Orenstein A, Brandt L . The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2008; 59(3):325-32. DOI: 10.1136/gut.2008.167270. View

Martoni C, Srivastava S, Leyer G . DDS-1 and UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients. 2020; 12(2). PMC: 7071206. DOI: 10.3390/nu12020363. View

Hosseini A, Nikfar S, Abdollahi M . Probiotics use to treat irritable bowel syndrome. Expert Opin Biol Ther. 2012; 12(10):1323-34. DOI: 10.1517/14712598.2012.707179. View

Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L . Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2006; 13(1):35-7. DOI: 10.1038/nm1521. View

Chey W, Kurlander J, Eswaran S . Irritable bowel syndrome: a clinical review. JAMA. 2015; 313(9):949-58. DOI: 10.1001/jama.2015.0954. View

Cao Y, Feng L, Liu Y, Jiang K, Zhang M, Gu Y . Effect of GG supernatant on serotonin transporter expression in rats with post-infectious irritable bowel syndrome. World J Gastroenterol. 2018; 24(3):338-350. PMC: 5776395. DOI: 10.3748/wjg.v24.i3.338. View

10.

Yoon J, Cha J, Oh J, Tan P, Kim S, Kwak M . Probiotics Ameliorate Stool Consistency in Patients with Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled Study. Dig Dis Sci. 2018; 63(10):2754-2764. DOI: 10.1007/s10620-018-5139-8. View

11.

Choi E, Lee H, Kim W, Han K, Iwasa M, Kobayashi K . Enterococcus faecalis EF-2001 protects DNBS-induced inflammatory bowel disease in mice model. PLoS One. 2019; 14(2):e0210854. PMC: 6394946. DOI: 10.1371/journal.pone.0210854. View

12.

Ducrotte P, Sawant P, Jayanthi V . Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012; 18(30):4012-8. PMC: 3419998. DOI: 10.3748/wjg.v18.i30.4012. View

13.

Su Y, Liu C, Fang H, Zhang D . Bacillus subtilis: a universal cell factory for industry, agriculture, biomaterials and medicine. Microb Cell Fact. 2020; 19(1):173. PMC: 7650271. DOI: 10.1186/s12934-020-01436-8. View

14.

Mawe G, Hoffman J . Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013; 10(8):473-86. PMC: 4048923. DOI: 10.1038/nrgastro.2013.105. View

15.

Black C, Drossman D, Talley N, Ruddy J, Ford A . Functional gastrointestinal disorders: advances in understanding and management. Lancet. 2020; 396(10263):1664-1674. DOI: 10.1016/S0140-6736(20)32115-2. View

16.

Sohn W, Lee O, Kwon J, Park K, Lim Y, Kim T . Tianeptine vs amitriptyline for the treatment of irritable bowel syndrome with diarrhea: a multicenter, open-label, non-inferiority, randomized controlled study. Neurogastroenterol Motil. 2012; 24(9):860-e398. DOI: 10.1111/j.1365-2982.2012.01945.x. View

17.

Bonfrate L, Di Palo D, Celano G, Albert A, Vitellio P, De Angelis M . Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients. Eur J Clin Invest. 2020; 50(3):e13201. DOI: 10.1111/eci.13201. View

18.

Tada Y, Ishihara S, Kawashima K, Fukuba N, Sonoyama H, Kusunoki R . Downregulation of serotonin reuptake transporter gene expression in healing colonic mucosa in presence of remaining low-grade inflammation in ulcerative colitis. J Gastroenterol Hepatol. 2015; 31(8):1443-52. DOI: 10.1111/jgh.13268. View

19.

Sarowska J, Choroszy-Krol I, Regulska-Ilow B, Frej-Madrzak M, Jama-Kmiecik A . The therapeutic effect of probiotic bacteria on gastrointestinal diseases. Adv Clin Exp Med. 2013; 22(5):759-66. View

20.

Ford A, Sperber A, Corsetti M, Camilleri M . Irritable bowel syndrome. Lancet. 2020; 396(10263):1675-1688. DOI: 10.1016/S0140-6736(20)31548-8. View